Inovio climbs on positive FDA feedback for co's respiratory disease therapy

Inovio Pharmaceuticals

10/10/2023 13:40

** Shares of drug developer Inovio  INO.O  rise ~8.7% to 39
cents premarket
    ** The U.S. FDA said early-stage data from Inovio's RRP
treatment trial can be used to submit a marketing application
for review under the FDA's accelerated approval program - INO
    ** Says co will be required to initiate a confirmatory trial
prior to submission and satisfy all other FDA filing
requirements
    ** Inovio says the FDA advised co's previously planned
late-stage trial would not be required to support this
submission
    ** RRP is characterized by the development of small,
wart-like growths, or papillomas, in the respiratory tract
    ** Up to last close, Inovio shares down 77% YTD
    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))